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Impaired degradation of amyloid beta (Ab) peptides
could lead to Ab accumulation, an early trigger of Alz-
heimer’s disease (AD). How Ab-degrading enzymes
are regulated remains largely unknown. Cystatin C
(CysC, CST3) is an endogenous inhibitor of cysteine
proteases, including cathepsin B (CatB), a recently
discovered Ab-degrading enzyme. A CST3 polymor-
phism is associated with an increased risk of late-on-
set sporadic AD. Here, we identified CysC as the key
inhibitor of CatB-induced Ab degradation in vivo. Ge-
netic ablation ofCST3 in hAPP-J20 mice significantly
lowered soluble Ab levels, the relative abundance of
Ab1-42, and plaque load. CysC removal also attenu-
ated Ab-associated cognitive deficits and behavioral
abnormalities and restored synaptic plasticity in the
hippocampus. Importantly, the beneficial effects of
CysC reduction were abolished on a CatB null back-
ground, providing direct evidence that CysC regu-
lates soluble Ab and Ab-associated neuronal deficits
through inhibiting CatB-induced Ab degradation.
INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease that causes loss of cognitive function (Hardy and Selkoe,
2002; Mattson, 2004; Roberson and Mucke, 2006). Amyloid beta
(Ab) peptides play a central role in AD pathogenesis (Hardy and
Selkoe, 2002), and soluble Ab assemblies may be early triggers
of amyloid toxicity (Kayed et al., 2003; Klein, 2002; Klyubin
et al., 2004; Lesne et al., 2006; Shankar et al., 2008). Ab accumu-
lation in AD brains could reflect overproduction or inefficient
clearance (Tanzi et al., 2004). In most sporadic and late-onset
AD cases lacking familial mutations in APP or presenilin (PS) 1,
high cerebral Ab levels could result from age-related defects in
Ab clearance (Selkoe, 2001; Tanzi et al., 2004). Thus, promoting
the endogenous pathways of Ab degradation and clearance
may be an effective strategy to reduce Ab levels. SeveralAb-degrading enzymes, including insulin-degrading enzyme,
neprilysin, endothelin-converting enzyme, plasmin, metallopro-
tease 9, and angiotensin-converting enzyme, have been impli-
cated in cerebral Ab clearance (Eckman et al., 2001; Iwata et al.,
2001; Qiu et al., 1998; Tucker et al., 2000; Yin et al., 2006; Zou
et al., 2007). However, little is known about how their Ab-degra-
dation activities are regulated in the brain (Saito et al., 2005),
and strategies to enhance their activities in vivo are lacking.
We identified cathepsin B (CatB) as a protease that effectively
degrades Ab assemblies (Mueller-Steiner et al., 2006). Ablation
of CatB in mice overexpressing human amyloid precursor protein
(hAPP) with familial AD-linked mutations increased plaque load,
the relative abundance of Ab1-42, and neuronal deficits (Mueller-
Steiner et al., 2006). Importantly, CatB reduces Ab levels by
inducing C-terminal truncation of Ab1-42 (Mueller-Steiner et al.,
2006). These findings suggest that enhancing endogenous
CatB activity could reduce levels of Ab, especially Ab1-42, and
protect against AD-related deficits.
We hypothesize that CatB enzymatic activity can be enhanced
by reducing levels of cystatin C (CysC, CST3) (Cimerman et al.,
1999; Turk et al., 1995), a cysteine protease inhibitor. Genetic
linkage studies showed an association between aCST3polymor-
phism and increased risk of late-onset sporadic AD, which was
later supported by systematic meta-analyses (Bertram et al.,
2007; Beyer et al., 2001; Crawford et al., 2000; Finckh et al.,
2000). Interestingly, overexpression of human CysC in hAPP-
J20 mice reduces plaque load by inhibiting Ab fibril formation
(Kaeser et al., 2007; Mi et al., 2007). The effects of endogenous
CysC on levels of soluble Ab and Ab1-42 and associated func-
tional deficits, however, remained unknown. In the current study,
we tested the hypothesis that CysC regulates levels of soluble Ab
and associated neuronal and behavioral deficits by inhibiting
CatB.
RESULTS
CysC Reduction Elevates CatB Activity
and Lowers Soluble Ab Levels
To directly assess the effect of CysC on CatB activity in the brain,
we compared CatB’s enzymatic activities in the hippocampus of
CST3+/+,CST3+/, andCST3/mice (Huh et al., 1999). RemovalNeuron 60, 247–257, October 23, 2008 ª2008 Elsevier Inc. 247
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activities in a gene dose-dependent manner (Figure 1A).
We next examined the effects of CysC removal on Ab levels in
primary cortical cultures. Since CysC is mainly expressed by
glia, we used mixed primary cortical cultures with neurons and
glia (Chen et al., 2005). CST3/ and CST3+/+ cultures were
infected with an adenoviral vector encoding hAPP cDNA with
the familial London mutation (V642I) but lacking the Swedish
Figure 1. CysC Reduction Increases CatB Activity and Lowers
Soluble Ab Levels
(A) CatB activities in hippocampal lysates from CST3+/+, CST3+/, or CST3/
mice (n = 6, ***p < 0.001, one-way ANOVA with Tukey-Kramer post hoc test).
(B) ELISA measurements of Ab1-42 or Ab1-x in the supernatants of primary
cortical cultures (CST3+/+ or CST3/) infected with hAPPV642I adenovirus.
All measurements were normalized to protein concentrations in the cell lysates
(n = 4, **p < 0.01, Mann-Whitney U test. Average Ab levels in CST3+/+ cultures
were arbitrarily set at 1).
(C–E) ELISA measurements of hippocampal levels of soluble Ab1-x and
Ab1-42 in 2- to 4-month-old hAPP-J20 mice. Deleting one or both alleles of
CST3 significantly reduced levels of soluble Ab1-x (C) and Ab1-42 (D). Ablating
CysC also reduced Ab1-42/Ab1-x ratios significantly (E). n = 9–21 mice/
genotype. ***p < 0.001; **p < 0.01, *p < 0.05, one-way ANOVA with Tukey-
Kramer post hoc test.
Values are mean ± SEM (A–E).248 Neuron 60, 247–257, October 23, 2008 ª2008 Elsevier Inc.mutations. Levels of Ab1-42, but not Ab1-x, were significantly
lower in supernatants from CST3/ cultures (Figure 1B), consis-
tent with higher CatB activity.
To determine the effects of endogenous CysC on soluble Ab
levels in vivo, we genetically reduced CysC levels by crossing
CST3/ mice with hAPP-J20 mice (Mucke et al., 2000). Soluble
Ab levels were quantified in hAPP/CST3+/+, hAPP/CST3+/, and
hAPP/CST3/mice at 2–4 months of age, before Ab deposition.
Reducing CysC significantly lowered levels of both soluble Ab
(Ab1-x) (Figure 1C) and Ab1-42 (Figure 1D) in a gene dose-
dependent manner (a greater reduction after removal of two
alleles than removal of one allele). Notably, CysC ablation signif-
icantly reduced the relative abundance of Ab1-42 (Figure 1E),
suggesting that CysC ablation exerts a more robust effect on
Ab1-42 than total Ab, as in primary cortical cultures.
CysC Ablation Reduces Total Plaque Load
in hAPP-J20 Mice
The formation of amyloid plaques in aging brains is enhanced by
increases in Ab, the relative abundance of Ab1-42, and fibrilliza-
tion. In agreement with the Ab/Ab42-lowering effects of CysC ab-
lation (Figure 1), the average amount of 3D6-labeled Ab deposits
in the hippocampus was markedly lower in hAPP/CST3/ mice
than in hAPP/CST3+/+ mice at both 5–8 and 8–10 months of age
(Figures 2A and 2B). Since plaques increased exponentially, we
ran multivariate loglinear regressions of plaque load against
both age and genotype to adjust for the age effects (Figure 2C).
Notably, the linear regression of logarithm-transformed plaque
load in hAPP/CST3+/+ mice was markedly different from that in
hAPP/CST3/mice (Figure 2C). Subsequent statistical analyses
performed in SPSS confirmed that age-adjusted plaque load in
hAPP/CST3+/+ mice was significantly higher than that in hAPP/
CST3/ mice (genotype coefficient b2 = 1.015, t = 6.217,
p < 0.001, see Table S1 in Supplemental Data online for details).
In cortex, CysC ablation also lowered 3D6-positive plaque load
in 8- to 10-month-old hAPP-J20 mice (Figure 2D).
Unlike 3D6 antibody, which labels both diffused and fibrillar
Ab, thioflavin S predominantly labels Ab fibrils (Figure 2E). Delet-
ing CysC reduced thioflavin S-positive Ab fibrils in hAPP-J20
mice at 5–8 months of age, but not at 8–10 months of age (Fig-
ures 2E and 2F). CysC removal in 8- to 10-month-old hAPP-
J20 mice lowered the levels of Ab and the relative abundance
of Ab1-42 in the TBS-extractable, but not TBS-insoluble pools
(Figure S1). These results suggest that CysC may affect soluble
Ab and fibrillar Ab differently. Indeed, human CysC overexpres-
sion inhibits Ab fibrillization by directly binding to Ab (Kaeser
et al., 2007; Mi et al., 2007), independently of its function as a
cysteine protease inhibitor.
CysC Ablation Does Not Affect the Processing of hAPP
with or without FAD Mutations
To determine whether CysC ablation affects APP processing, we
compared the levels of metabolic fragments of hAPP in hAPP/
CST3+/+ and hAPP/CST3/ mice by western blot analysis.
The levels of a-sAPP, detected with 8E5 antibody (Esposito
et al., 2004), or those of b-C-terminal fragments (b-CTF), de-
tected with CT-15 antibody, were not affected by CysC ablation
in hAPP-J20 mice (Figures 3A–3C). The subtle increase in the
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Cystatin C Inhibits Ab Degradation by Cathepsin BFigure 2. CysC Ablation in hAPP-J20 Mice Lowers Total Plaque Deposition
(A and E) Photomicrographs of 3D6 immunostaining (A) or thioflavin S staining (E) in the hippocampus of a 5- to 8-month-old hAPP/CST3+/+ or hAPP/CST3/
mouse.
(B, D, and F) Quantification of plaque load labeled with 3D6 (B and D) or thioflavin S (F) in 5- to 8-month-old and 8- to 10-month-old hAPP/CST3+/+ or
hAPP/CST3/mice. n = 9–15 mice/genotype. **p < 0.01, *p < 0.05, unpaired t test. For total plaque load, three hippocampal (B) or cortical (D) sections per mouse
were analyzed to determine the percent area covered by 3D6-immunoreactive material. The number of thioflavin S-positive plaques was counted in five
hippocampal sections per mouse (F). Values are mean ± SEM.
(C) Linear regression of the logarithm-transformed plaque load against age (5–10 month) and genotype (as a dummy variable). The regression was fitted to the
following model: Log (plaque load) = (–7.912) + (0.892) 3 age + (1.015) 3 genotype (dummy). The age-adjusted plaque load in hAPP/CST3+/+ mice (genotype
dummy = 1) was significantly higher than that in hAPP/CST3/ mice (genotype dummy = 0), since the b2 coefficient (1.015) is significantly larger than
0 (t = 6.217, p < 0.001). n = 23–25 mice/genotype.levels of a-CTF in hAPP/CST3/ mice did not reach statistical
significance (p > 0.05, data not shown). These results indicate
that CysC does not affect the processing of hAPP with Swedish
and Indiana mutations, consistent with a previous report (Mi
et al., 2007). Importantly, CysC ablation had no effect on the
processing of wild-type hAPP either. Levels of b-CTF, a-CTF,
or full-length hAPP (FL-hAPP) were similar in lysates from
CST3/ andCST3+/+ cultures infected with an adenoviral vector
encoding wild-type hAPP cDNA (Figure 3D). Notably, hAPP was
cleaved predominantly at the a-secretase site, owing to the lack
of Swedish mutations at the b-secretase site (Figure 3D).
CysC Ablation Prevents Premature Mortality
and Ab-Associated Cognitive Deficits
Mice expressing high levels of hAPP and Abdie prematurely (Chin
et al., 2005; Hsiao et al., 1995; Roberson et al., 2007). Although
the etiology is unknown, premature mortality was prevented by
lowering Ab levels or altering downstream pathways (Leissring
et al., 2003; Roberson et al., 2007). Indeed, both hAPP/CST3/
and hAPP/CST3+/ mice, with lower soluble Ab levels, were
protected from the early mortality seen in hAPP/CST3+/+ mice
(Figure 4A).
We next asked whether CysC reduction improves cognitive
function in hAPP-J20 mice, which develop Ab-associated deficits
in spatial learning and memory (Cheng et al., 2007; Chin et al.,
2005; Roberson et al., 2007). Spatial learning was measured in
the hidden-platform version of the Morris water maze in ten
sessions over 5 days. Control mice that do not express hAPPlearned this task by day 3 (session 6), regardless of the CST3 ge-
notype (Figure 4B). The escape latency of hAPP/CST3+/+ mice
was considerably longer than that of control mice (Figure 4B), in-
dicating Ab-associated spatial learning deficits. Deleting CysC in
hAPP-J20 mice significantly reduced the escape latency and
improved the learning curve (Figure 4B). As CST3+/+, CST3/,
hAPP/CST3+/+, and hAPP/CST3/mice swam at similar speeds
(Figure S2), the differences in their learning curves were not
confounded by their swim speed.
To measure spatial memory retention, we performed probe
trials by removing the hidden platform 1 day after the training.
hAPP/CST3+/+mice crossed the target platform many fewer
times than wild-type mice (CST3+/+), indicating impaired mem-
ory retention (Figure 4C). CysC ablation in hAPP-J20 mice
markedly increased the number of target platform crossings,
suggesting that spatial memory was restored in hAPP/CST3/
mice (Figure 4C). Indeed, hAPP/CST3/ mice spent signifi-
cantly more time in the target quadrant than hAPP/CST3+/+
mice, similar to mice without hAPP (Figure 4D). Thus, Ab-associ-
ated deficits in spatial learning and memory were prevented by
CysC removal. In the cued (nonspatial) sessions after the probe
trials, mice learned to find a target platform that was clearly
visible with a marker placed directly above it. In agreement
with previous studies (Cheng et al., 2007; Roberson et al.,
2007), hAPP/CST3+/+ mice took longer time than CST3+/+ mice
to locate the visible platform (Figure S2). Removing CysC signif-
icantly improved the ability of hAPP-J20 mice to learn this task
(Figure S2).Neuron 60, 247–257, October 23, 2008 ª2008 Elsevier Inc. 249
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attenuated by CysC reduction. Increased exploratory locomotor
activity was observed in several independent AD animal models
(Kobayashi and Chen, 2005), including Tg2576 (Ognibene et al.,
2005) and hAPP-J20 mice (Cheng et al., 2007; Chin et al., 2005;
Roberson et al., 2007). In an open field test, hAPP-J20 mice
exhibited sustained locomotor hyperactivity over the course of
15 min (Figure 4E). The lack of habituation to the novel environ-
ment suggests impaired nonassociative learning. Removing
CysC in hAPP-J20 mice restored habituation, suggesting im-
proved nonassociative learning in this paradigm (Figure 4E).
The total locomotor hyperactivity of hAPP-J20 mice was also
significantly attenuated by CysC reduction (Figure 4F). In the
elevated plus maze, hAPP-J20 mice exhibited a disinhibition
phenotype, spending more time in the open arms than the con-
trol mice (Figure 4G), as expected from previous studies (Cheng
et al., 2007; Chin et al., 2005; Roberson et al., 2007). The relative
amount of time spent in the open arms was markedly decreased
in hAPP/CST3/ mice and, to lesser extent, in hAPP/CST3+/
mice (Figure 4G). Thus, the CysC reduction ameliorated the
Figure 3. CysC Ablation Does Not Affect the Processing of hAPP
(A) Western blot analyses of cortical lysates demonstrate comparable levels of
hAPP metabolic fragments in 5- to 8-month-old hAPP/CST3+/+ and hAPP/
CST3/ mice.
(B and C) Quantification of levels of b-CTFs (B) and a-CTFs (C) relative to those
of GAPDH in hAPP/CST3+/+ (n = 9) and hAPP/CST3/ mice (n = 7). Values are
mean ± SEM.
(D) Western blot analyses demonstrate comparable levels of hAPP metabolic
fragments in the lysates of CST3+/+ or CST3/ primary cortical cultures
infected with an adenoviral vector expressing wild-type hAPP. GAPDH was
used as a loading standard.250 Neuron 60, 247–257, October 23, 2008 ª2008 Elsevier Inc.disinhibition phenotype of hAPP-J20 mice in a gene dose-
dependent manner.
CysC Ablation Ameliorates Ab-Associated Neuronal
and Synaptic Deficits in Hippocampal Circuits
Cognitive deficits in hAPP-J20 mice are associated with deple-
tion of a calcium-binding protein, calbindin-D28k, in the DG
(Palop et al., 2003, 2007; Roberson et al., 2007). Reducing
CysC in hAPP-J20 mice significantly increased calbindin levels
in the DG (Figures 5A and 5B), confirming improved hippocam-
pal function. Removal of one or both alleles of CysC also signif-
icantly increased the number of Fos-positive neurons in the DG
of hAPP-J20 mice (Figure S3).
To directly assess the effects of CysC reduction on functional
deficits in hippocampal circuits, we performed extracellular
recordings of field excitatory postsynaptic potentials (EPSPs) of
two hippocampal circuits, the perforant path to DG granule cell
synapses and the Schaffer collateral to CA1 pyramidal cell
synapses. In the medial perforant path (MPP) to granule cell syn-
apses, long-term potentiation (LTP) induced by theta burst
stimulation was significantly depressed in hAPP-J20 mice com-
pared with nontransgenic controls (Palop et al., 2007) (Figure 5C).
CysC removal in hAPP-J20 mice led to a robust recovery of LTP
(Figure 5C), suggesting improved long-term synaptic plasticity in
the DG. In the lateral perforant path (LPP) to DG synapses of
hAPP-J20 mice, alterations of paired-pulse facilitation (PPF),
which reflect deficits in short-term plasticity, were also prevented
by CysC removal (Figure 5D).
Interestingly, the strength of basic synaptic transmission in the
DG, as measured by input/output (I/O) relationships at the MPP
pathway, was not affected by either hAPP overexpression or
CysC ablation (Figure 5E). In contrast, the I/O ratios of the
Schaffer collateral to CA1 synapses were markedly reduced in
hAPP-J20 mice, but ablating CysC failed to improve the synaptic
strength of this synaptic pathway (Figure 5F). These results
demonstrated that CysC deletion in hAPP-J20 mice specifically
restored both long-term and short-term synaptic plasticity in the
hippocampal circuits involving the DG, providing plausible
molecular mechanisms for the improvements in spatial learning
and memory and other hippocampus-associated behaviors.
CysC Regulates Soluble Ab in a CatB-Dependent
Manner
CysC has multiple biological activities, and its regulation of Ab
levels could still be independent of CatB. To directly prove that
beneficial effects of CysC reduction are mediated by enhancing
CatB activity, we examined the effects of CysC reduction in the
absence of CatB. CatB was genetically deleted by backcrossing
hAPP/CST3+/+, hAPP/CST3+/, hAPP/CST3/ mice and their
littermate controls (CST3+/+, CST3+/, CST3/) onto a CatB
null background.
In 2- to 3-month-old hAPP-J20 mice lacking CatB, CysC
reduction had no effect on the levels of soluble Ab1-x and Ab1-
42 or the relative abundance of Ab1-42 (Figures 6A and 6B).
Thus, CysC reduction lowered Ab levels in a CatB-dependent
manner. Notably, CatB ablation elevated the relative abundance
of Ab1-42 only when CysC levels were reduced (Figure 6B),
providing further evidence that CatB-induced proteolytic
Neuron
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tional Deficits in hAPP-J20 Mice
(A) Kaplan-Meier survival curves showing the ef-
fect of CysC reduction on survival of hAPP-J20
mice. All genotyped mice in the colony (n = 466)
were included in the analysis. By log-rank compar-
ison, only hAPP/CST3+/+ mice differed from all
other groups (p < 0.0001). Mon, months.
(B–D) Effects of CysC ablation on learning and
memory in water maze testing (n = 6–7 male
mice/genotype, 7–10 months of age). (B) Hidden
platform learning curves differed by genotype (re-
peated-measures ANOVA: p < 0.0001). In Tukey-
Kramer post hoc comparisons, hAPP/CST3+/+ dif-
fered from CST3+/+ and CST3/ mice (p < 0.001);
hAPP/CST3/ differed from hAPP/CST3+/+ (p <
0.01) but not from CST3+/+ or CST3/ mice. (C)
Number of target platform crossings differed by
genotype in the probe trials (two-way ANOVA,
hAPP and CST3 interaction, p < 0.05). In Bonfer-
roni post hoc comparisons, hAPP/CST3+/+ dif-
fered from CST3+/+ mice (*p < 0.05); hAPP/
CST3/ differed from hAPP/CST3+/+ (*p < 0.05),
but not from CST3+/+ or CST3/ mice. (D) Per-
centage of time spent in the target quadrant dif-
fered by genotype (two-way ANOVA, hAPP and
CST3 interaction, p < 0.05). In Bonferroni post
hoc comparisons, hAPP/CST3/ differed from
hAPP/CST3+/+ mice (*p < 0.05), but not from
CST3+/+ or CST3/ mice.
(E–G) Effects of CysC reduction in open field tests
and elevated plus maze (n = 5–10 male mice/geno-
type; 3–4 months of age). (E) The ambulatory activ-
ity per min differed by genotype (repeated-mea-
sures ANOVA, p < 0.001). In Tukey-Kramer post
hoc comparisons, hAPP/CST3+/+ differed from
CST3+/+ or CST3/ (p < 0.001), hAPP/CST3+/+
differed from hAPP/CST/ (p < 0.001). Min, min-
utes. (F) Total ambulatory activity over 15 min
differed by genotype (two-way ANOVA; Bonferroni
post hoc comparisons, hAPP/CST3+/+ versus
CST3+/+ *, p < 0.05; hAPP/CST3/ versus
hAPP/CST3+/+, *p < 0.05). (G) The percentage of
time spent in the open arms of an elevated plus
maze differed by genotype (two-way ANOVA;
Bonferroni post hoc comparisons, hAPP/CST3+/+
versus CST3+/+, *p < 0.05; hAPP/CST3/ versus
hAPP/CST3+/+, *p < 0.05).
Values are mean ± SEM (B–G).truncations of Ab1-42 are normally suppressed by endogenous
CysC. In addition, CysC reduction failed to lower 3D6-positive
plaque load in 4- to 6-month-old hAPP mice without CatB
(Figure 6C). Indeed, the linear regression of logarithm-trans-
formed plaque load in hAPP/CST3+/+/CatB/mice did not differ
from that in hAPP/CST3//CatB/ mice (Figure 6D). Multivari-
ate loglinear regression analyses demonstrated no difference
between age-adjusted plaque load of these two genotypes
(genotype coefficient b2 =0.111, t =0.258, p = 0.8, see Table
S2 for statistical details). These results identified enhancedAb-degrading activity of CatB as the mechanism for the Ab-low-
ering effects of CysC reduction.
Neuroprotective Effects of CysC Ablation
Depend on CatB
To further establish that the beneficial effects of CysC reduction
are due to enhanced CatB activity, we determined whether the
effects of CysC reduction on the expression of DG neuronal
markers in hAPP-J20 mice depended on CatB. Without CatB,
CysC reduction failed to increase expression of calbindinNeuron 60, 247–257, October 23, 2008 ª2008 Elsevier Inc. 251
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Cystatin C Inhibits Ab Degradation by Cathepsin BFigure 5. CysC Ablation Ameliorates Ab-Associated
Neuronal and Synaptic Deficits in Hippocampal
Circuits
(A) Photomicrographs of calbindin immunostaining in the
hippocampus of a 5- to 8-month-old hAPP/CST3+/+, hAPP/
CST3/, CST3+/+, or CST3/ mouse.
(B) Effects of CysC reduction on the relative calbindin levels in
the DG (n = 27–46 mice/genotype, age 2–8 months; two-way
ANOVA: p < 0.0001, hAPP and CST3 interaction). In post hoc
comparisons, hAPP/CST3+/+ differed from groups without
hAPP (***p < 0.001); hAPP/CST3/ differed from hAPP/
CST3+/+ (***p < 0.001), but not from all groups without hAPP;
hAPP/CST3+/ differed from hAPP/CST3+/+ (*p < 0.05). CB,
calbindin.
(C–F) Effects of CysC ablation on the synaptic functions at the
perforant path to DG synapses (C–E) or at the Schaffer
collateral to CA1 synapse (F) (n = 8–12 slices from 2–3 mice/
genotype). (C) LTP at the medial perforant path was signifi-
cantly depressed in hAPP/CST3+/+ mice; deleting CysC in
hAPP-J20 mice led to a significant recovery (p < 0.05,
CST3+/+ versus hAPP/CST3+/+; p < 0.05, hAPP/CST3+/+ ver-
sus hAPP/CST3/; Tukey’s post hoc analysis on repeated-
measures ANOVA for data collected from minutes 61–70).
(Inset) Representative fEPSP before (solid line) and after
(dashed line) the theta burst stimulation (from left to right:
CST3+/+, hAPP/CST3+/+, hAPP/CST3/). (D) Paired-pulse
facilitation at the lateral perforant pathway was markedly
reduced in hAPP/CST3+/+ mice; deleting CysC in hAPP-J20
mice led to a significant recovery (p < 0.01, CST3+/+ versus
hAPP/CST3+/+; p < 0.01, hAPP/CST3+/+ versus hAPP/
CST3/; one-way ANOVA at 50 and 100 ms interpulse inter-
vals). (Inset) Representative responses to the first stimulus
(P1, solid line) and to the second stimulus (P2, dashed line)
(from left to right: CST3+/+, hAPP/CST3+/+, and hAPP/
CST3/). (E) The synaptic strength at the medial perforant
path was not affected by expression of hAPP or deletion of
CST3. (F) CysC deletion did not restore the synaptic transmis-
sion along the Schaffer collateral-CA1 synapse, which was
significantly impaired in hAPP/CST3+/+ mice (p < 0.01,
CST3+/+ versus hAPP/CST3+/+, ANOVA).
Values are mean ± SEM (B–F).(Figures 7A and 7B) or the number of Fos-positive neurons (Fig-
ure S4) in the DG. The lack of improvements was expected since
levels of Ab/Ab1-42 remained similarly high in these animals
regardless of the CST3 genotype (Figures 6A and 6B).
Electrophysiological recordings further revealed that CatB
was required for CysC ablation to protect against Ab-associated
functional deficits. With CatB, CysC removal restored LTP and
PPF in DG synapses (Figures 5C and 5D). Without CatB, CysC
removal failed to restore LTP at MPP to granule cell synapses
(Figure 7C) or to prevent the alterations of PPF in LPP to granule
cell synapses (Figure 7D). These findings establish a critical role
for the CysC-CatB axis in regulating the levels of soluble Ab and
associated functional deficits.
DISCUSSION
This study shows that CysC is a key inhibitor of CatB-dependent
Ab degradation in vivo. CysC removal is highly effective in pro-
moting CatB-dependent truncation of Ab1-42, the most patho-
genic form among the different Ab peptides in the brain (Golde
et al., 2000). Levels of Ab1-42 were significantly lower in cultures252 Neuron 60, 247–257, October 23, 2008 ª2008 Elsevier Inc.from CysC-deficient mice than in cultures from the wild-type
mice. CysC removal lowered the relative abundance of Ab1-42
in hAPP-J20 mice with CatB but not in those lacking CatB.
Conversely, inhibiting CatB activity in young hAPP-J20 mice
increased the relative abundance Ab1-42, but only when CysC
levels were reduced. Thus, the relative abundance of Ab1-42 is
modulated by CysC-CatB axis and CatB-induced Ab1-42
truncation is normally suppressed by endogenous CysC in vivo.
These findings further prove that CatB is an Ab-degrading
enzyme (Mueller-Steiner et al., 2006). In contrast, a recent study
reported that nonspecific inhibitors of cysteine proteases re-
duced Ab levels and b-secretase site cleavage of wild-type
hAPP, claiming an involvement of CatB in APP processing
(Hook et al., 2008). However, in light of the nonspecific inhibitors
used (Bogyo et al., 2000; Montaser et al., 2002) and the results of
our studies, it is unlikely that CatB fulfills such a function. Indeed,
in CST3/ cells expressing hAPPV642I without the Swedish
mutations, higher CatB activity led to markedly lower Ab1-42
levels but had no effects on levels of b-CTF, suggesting that
CatB does not induce cleavage at the wild-type b-secretase
site in primary neurons. Overexpressing CatB in aged hAPP
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Reduction Depend on CatB
(A) ELISA measurements of levels of soluble
Ab1-42 and Ab1-x in the hippocampus of 2- to
3-month-old hAPP/CST3+/+/CatB/, hAPP/
CST3+//CatB/, and hAPP/CST3//CatB/
mice (n = 6–10 mice/genotype). CysC reduction
had no effects on the levels of Ab1-x or Ab1-42
in hAPP-J20 mice lacking CatB.
(B) CatB ablation increased the ratios of Ab1-42/
Ab1-x in hAPP-J20 mice with one or both alleles
of CST3 deleted (n = 6–21 mice/genotype, age
2–4 months; two-way ANOVA: ***p < 0.001, **p <
0.01, Bonferroni post hoc test of CatB’s effects).
(C) Normalized plaque load in hippocampus of 4-
to 6-month-old hAPP/CST3+/+/CatB/, hAPP/
CST3+//CatB/, and hAPP/CST3//CatB/
mice (n = 7–14 mice/genotype; one-way ANOVA,
p > 0.1). Average plaque load in hAPP/CST3+/+/
CatB/ mice was arbitrarily set at 1.
Values are mean ± SEM (A–C).
(D) Linear regression of the logarithm-transformed
plaque load against both age and genotype (as
a dummy variable). The regression was fitted to
the following model: Log (plaque load) =
(14.547) + (2.052) 3 age + (0.111) 3 genotype
(dummy). The age-adjusted plaque load in hAPP/
CST3+/+/CatB/ mice (genotype dummy = 1)
did not differ from that in hAPP/CST3//CatB/
mice (genotype dummy = 0), since the b2 coeffi-
cient (0.111) is not significantly different from
0 (t = 0.258, p = 0.8). n = 7–10 mice/genotype.transgenic mice reversed preexisting amyloid pathology, further
supporting the efficacy of CatB in degrading Ab aggregates and
the therapeutic potential of enhancing CatB activity (Mueller-
Steiner et al., 2006). Moreover, ablation of BACE1 completely
abolished the b-secretase site processing and Ab generation in
PDAPP mice, which overexpress hAPPV717F without the Swed-
ish mutations (McConlogue et al., 2007). These results provide
compelling evidence that CatB exhibits no significant b-secre-
tase activity in vivo regardless of the presence or absence of
Swedish mutations on hAPP.
Removing CysC in hAPP-J20 mice is highly effective in pre-
venting spatial learning and memory deficits and restoring syn-
aptic plasticity in hippocampal circuits, most likely by enhancing
CatB-dependent Ab degradation and lowering levels of soluble
Ab and Ab42. Indeed, the protective effects of CysC ablation
were abolished in hAPP mice without CatB, which had similarly
high levels of soluble Ab and Ab42 regardless of CST3 genotype.
Specific species of soluble Ab oligomers, including low-n and
high-n Ab assemblies, have emerged as early and potent triggers
of AD-related functional deficits (Kayed et al., 2003; Klein, 2002;
Klyubin et al., 2004; Lesne et al., 2006; Shankar et al., 2008;
Townsend et al., 2006; Walsh and Selkoe, 2007). It remains to
be defined how different species of Ab oligomers are regulated
by the CysC-CatB axis. Notably, our study shows that not all
functional deficits in hAPP-J20 mice are prevented by CysC
ablation. For example, CysC deletion improved LTP and amelio-
rated alterations in PPF in the perforant path to granule cell
synapse, but it failed to improve the synaptic strength in the
Schaffer collateral to CA1 pyramidal cell synapse. One likely ex-planation is that, even at reduced levels, Ab in hAPP/CST3/
mice is sufficient to impair the basic synaptic transmission in
the CA1. In support of this notion, the I/O ratios of the CA1
synapse were also impaired in hAPP-H6 mice (Hsia et al.,
1999), in which soluble Ab levels were only 20%–30% of those
in APP-J20 mice (Mucke et al., 2000). However, the deficit at
CA1 may also be caused by CTFs or certain Ab oligomeric
species that are not affected by CysC ablation. Further studies
will be required to assess these possibilities.
We found that the marked reduction in plaque load induced by
CysC ablation depends on CatB. Surprisingly, overexpressing
human CysC also reduced plaque load by inhibiting Ab fibril
formation (Kaeser et al., 2007; Mi et al., 2007). These puzzling ef-
fects could reflect the different mechanisms by which CysC reg-
ulates soluble and insoluble Ab—the former by inhibiting CatB
and the latter by binding to Ab (Kaeser et al., 2007; Mi et al.,
2007). Depending on the relative levels of CysC and CatB, either
mechanism may play a more prominent role. For example, since
the physiological concentration of endogenous CysC is much
higher than that of CatB (Turk et al., 2002), CysC reduction would
alter CatB activity much more effectively than CysC overexpres-
sion. Therefore, in hAPP-J20 mice with reduced CysC, the Ab-
lowering effects prevailed as a result of enhanced CatB activity,
leading to a marked decrease in overall Ab deposits. In contrast,
in hAPP-J20 mice overexpressing human CysC, CysC’s inhibi-
tory effects on Ab fibrillization probably superseded those on
CatB activity, also resulting in lower plaque loads without affect-
ing soluble Ab levels (Kaeser et al., 2007). Furthermore, the
balance of CysC’s effects on fibrillization versus those on CatBNeuron 60, 247–257, October 23, 2008 ª2008 Elsevier Inc. 253
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CysC Reduction Depend on CatB
(A) Photomicrographs of calbindin immuno-
staining in the hippocampus of 5-month-old
hAPP/CST3+/+/CatB/, hAPP/CST3//CatB/,
CST3+/+/CatB/, and CST3//CatB/, mice.
(B) CysC reduction failed to prevent the depletion
of DG calbindin levels in hAPP-J20 mice lacking
CatB (n = 9–22 mice/genotype, age 2–6 months
old; two-way ANOVA: ***p < 0.001, Bonferroni
post hoc test of the hAPP effects; CST3 effects,
not significant).
(C and D) Effects of CysC ablation on the synaptic
functions in hippocampus of hAPP-J20 mice on
CatB null background (n = 8–12 slices from
2 mice/genotype). (C) LTP at the medial perforant
path was significantly depressed in hAPP/
CatB/ mice regardless of CST3 genotype
(p < 0.01, CST3+/+/CatB/ versus hAPP/
CST3+/+/CatB/ and CST3//CatB/ versus
hAPP/CST3//CatB/). CysC removal did not
alter LTP (p > 0.1, hAPP/CST3+/+/CatB/ versus
hAPP/CST3//CatB/; Tukey’s post hoc analy-
sis on repeated-measures ANOVA for data
collected from minutes 61–70). (D) The paired-
pulse facilitations at the lateral perforant pathway
were markedly reduced in hAPP/CatB/ mice
regardless of CST3 genotype (p < 0.01,
CST3+/+/CatB/ versus hAPP/CST3+/+/CatB/;
CST3//CatB/ versus hAPP/CST3//CatB/;
one-way ANOVA at 50–100 ms interpulse intervals).
Values are mean ± SEM (B–D).could be affected by aging. Indeed, CatB activities in the brain of
hAPP-J20 mice appeared to decline with aging (Mueller-Steiner
et al., 2006), which may help explain why CysC ablation reduced
thioflavin S-labeled Ab fibrils in 5- to 8-month-old but not in 8- to
10-month-old brains.
Where CysC and CatB interact to regulate Ab catabolism
remains to be defined. CysC is a secreted protein found at high
levels in cerebrospinal fluid (CSF) (Abrahamson et al., 1986), sug-
gesting that it might inhibit the Ab-degrading activity of CatB
extracellularly. Notably, CysC and CatB are localized in amyloid
plaques (Cataldo and Nixon, 1990; Levy et al., 2001). Moreover,
CatB activity in the CSF is much greater in CST3 null than wild-
type mice (B.S. and L.G., unpublished data). However, CatB is
mainly localized in lysosomal and endosomal compartments,
suggesting that CysC may inhibit CatB-induced Ab degradation
intracellularly. In AD brains, immunoelectron microscopy with
anti-CysC antibodies revealed strongly labeled pyramidal neu-
rons that were immunopositive for intracellular Abx-42 (Levy
et al., 2001). In addition, neuronal CysC colocalized with CatB
in endosome/lysosomes (Deng et al., 2001), supporting the
notion that CysC inhibits endosomal CatB-dependent Ab degra-
dation. The CST3 polymorphism, which exhibits two common
haplotypes (A and B), offers intriguing clues about the involve-
ment of CysC-CatB axis in AD. B/B homozygosity is associated
with increased risk for developing late-onset sporadic AD (Ber-
tram et al., 2007; Beyer et al., 2001; Crawford et al., 2000; Finckh
et al., 2000). Pulse-chase experiments and high-resolution west-
ern blots demonstrated that intracellular CysC levels are higher in
B/B fibroblasts due to a reduced secretion of CysC (Benussi254 Neuron 60, 247–257, October 23, 2008 ª2008 Elsevier Inc.et al., 2003). The increase in intracellular CysC induced by B/B
homozygosity might impair CatB-dependent Ab degradation in
the endosomal/lysosomal pathways and contribute to Ab
accumulation.
The revelation that CysC regulates soluble Ab by inhibiting
CatB may lead to new Ab-lowering strategies that are highly
specific. For example, it might be possible to develop reagents
that specifically disrupt CysC-CatB interactions without affect-
ing CysC’s diverse biological activities, including inhibition of
other cysteine proteases or Ab fibrillization. Interestingly, even
partial reduction of CysC levels significantly reduced soluble
Ab levels, neuronal deficits, and premature mortality. These
results suggest that CysC plays a rate-limiting role in this newly
discovered Ab clearance pathway, making it an attractive target
for therapeutic intervention.
EXPERIMENTAL PROCEDURES
Mice
To remove CST3 genetically, CST3/ mice (57% C57BL/6 and 43% 129)
were crossed with hAPP-J20 mice (C57BL/6). The first cross resulted in
hAPP/CST3+/ mice, which were crossed with CST3+/ (CST3 heterozygotes
that do not express hAPP) to generate six genotypes: hAPP/CST3/, hAPP/
CST3+/+, hAPP/CST3+/, CST3/, CST3+/+, and CST3+/. These mice are on
a mixed genetic background (77.5% C57BL/6 strain and 22.5% 129 strain).
The strain background was determined with a panel of 110 microsatellite
markers that distinguishes between C57BL/6 and 129 (Genetic Testing
Services, Charles River). PCR-based genotyping for CST3 allele or hAPP
transgene was performed as described (Huh et al., 1999; Mucke et al., 2000).
To investigate the genetic interaction of CysC and CatB, we deleted CatB ge-
netically inhAPP/CST3/,hAPP/CST3+/+,hAPP/CST3+/,CST3/,CST3+/+,
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mice were generated by crossing CatB/ mice with CST3/ mice. (2)
CST3+//CatB+/ mice were then crossed with hAPP/CatB//CST3+/+, which
were generated from our previous study (Mueller-Steiner et al., 2006), to gener-
ate hAPP/CST3+//CatB/ or CST3+//CatB/. (3) Non-littermates hAPP/
CST3+//CatB/andCST3+//CatB/mice were then crossed with each other
to generate hAPP/CST3+/+, hAPP/CST3+/, and hAPP/CST3/ mice on
a CatB/ background (hAPP/CST3+/+/CatB/, hAPP/CST3+//CatB/ and
hAPP/CST3//CatB/) and littermate controls that do not express hAPP
(CST3+/+/CatB/, CST3+//CatB/ and CST3//CatB/mice).
Primary Cortical Culture and Adenoviral Infection
To generate mixed cortical culture, cortices from mouse pups of different
genotypes were isolated on postnatal day 0 or 1 and dissociated. Cells were
plated at 160,000 cells/ml in plating medium containing Dulbecco’s modified
Eagle’s medium, 10% fetal bovine serum, 0.5 mM Glutamax, 100 units/ml
penicillin, and 100 mg/ml streptomycin. To overexpress hAPP, an adenoviral
vector encoding human wild-type APP695 or APPV642I cDNA under the con-
trol of the cytomegalovirus promoter was used to infect neurons cultured from
CST3+/+ and CST3/ pups after 6 days in culture, when the medium was
replaced with Neurobasal A medium supplemented with N2 (NBA/N2). On
day 8, supernatants and cells were harvested for Ab ELISA, CatB activity
assay, and BCA protein assays. Unless noted otherwise, all cell-culture
supplies, medium, and antibiotics were from Invitrogen (Carlsbad, CA).
Immunohistochemistry and Quantitation
of Immunoreactive Structures
Experimenters were blind to the genotypes of the mice for all immunohisto-
chemical analyses. Expression of calbindin and Fos in the DG and 3D6-posi-
tive or thioflavin S-positive plaques were quantified as described with minor
modifications (Palop et al., 2003; Mueller-Steiner et al., 2006). Sections were
incubated with rabbit anti-calbindin (1:15,000, Swant, Bellinzona, Switzer-
land), anti-c-Fos (1:10,000, Ab-5, Calbiochem), biotinylated goat anti-rabbit
(1:200, Vector Laboratories, Burlingame, CA), or biotinylated mouse monoclo-
nal antibody 3D6 (5 mg/ml, Elan, South San Francisco, CA), after quenching
endogenous peroxidase activity. Binding of the antibody was detected with
the Elite kit (Vector Laboratories) with diaminobenzidine and H2O2 for develop-
ment. Images were obtained with a DEI-470 digital camera (Optronics, Goleta,
CA). The integrated optical density from three coronal sections was deter-
mined with a Bioquant image analysis system and averaged in two areas of
the molecular layer of the DG and of the stratum radiatum of the CA1 region,
in which calbindin levels remain stable. Calbindin levels were expressed as
the ratio of integrated optical density in the molecular layer and in the stratum
radiatum of the CA1. The relative number of Fos-positive neurons was deter-
mined by counting Fos-positive cells in the DG in every tenth serial coronal
section throughout the rostrocaudal extent of the DG. At least five coronal
sections were analyzed per mouse, and the average of the individual measure-
ments was used to calculate group means. Total plaque load was calculated
as the percent area of the hippocampus or cortex covered by 3D6-immunore-
active material. Thioflavin S-positive mature plaques were quantified by
counting the number of plaques in the hippocampus. Three coronal sections
were analyzed per mouse, and the average of the individual measurements
was used to calculate group means.
CatB Enzymatic Assay
Brain CatB activities were quantified as described (Mueller-Steiner et al.,
2006). Briefly, hippocampi from CST3/, CST3+/+, and CST3+/ mice were
lysed in lysis buffer in the absence of proteinase inhibitors, preactivated with
4 mM cysteine, and incubated with the synthetic substrate Z-Arg-Arg AMC
at 37C for 30 min. Released free AMC was determined fluorometrically. The
enzymatic activities inhibited by CA074 were defined as CatB-specific activi-
ties. Protein concentrations were measured with the BCA protein assay kit
(Pierce, Rockford, IL) and used to normalize CatB activities.
Western Blot Analysis
Mouse cortical samples were individually sonicated at 4C in buffer containing
10 mM HEPES (pH 7.4), 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 1 mM dithio-threitol, 1 mM or phenylmethylsulphonyl fluoride, 1 mM Na3VO4, 10 mg/ml
leupeptin, 10 mg/ml aprotinin, and 1% sodium dodecyl sulfate and centrifuged
at 5000 3 g (10 min). Equal amounts of protein (by BCA assay) were resolved
by SDS/PAGE and transferred to nitrocellulose membranes. After blocking,
membranes were labeled with rabbit anti-CT15 (1:1000, a kind gift of E.H.
Koo, University of California, San Diego), monoclonal antibody (mAb) anti-
hAPP (1:1,000, 8E5, Elan), or mAb anti-GAPDH (1:1000, Millipore, Billerica,
MA), and incubated with horseradish peroxidase-conjugated goat anti-rabbit
IgG (1:5000, Millipore) or goat anti-mouse IgG (1:10,000, Millipore). Bands
were visualized by enhanced chemiluminescence and quantitated by
densitometry and Quantity One 4.0 software (Bio-Rad, Hercules, CA).
Quantification of Ab
For quantification of Ab in young mice before plaque formation, snap-frozen
hippocampi were homogenized in guanidine buffer. In older mice after plaque
formation, soluble and insoluble fractions of Ab were quantified separately
after sequential extraction, as described (Leissring et al., 2003). Briefly, to ex-
tract soluble Ab, frozen hippocampi were homogenized with five volumes (w:v)
of 50 mM Tris-HCL (pH 7.4), and centrifuged at 100,000 3 g for 1 hr, and the
resulting supernatant was denatured with 5 M guanidine (1:3) for ELISA mea-
surement. To extract Tris-insoluble Ab, the resulting pellet was dissolved and
incubated in five volumes of guanidine buffer for 30 min, followed by centrifu-
gation at 100,0003 g for 1 hr. ELISAs were performed as described (Johnson-
Wood et al., 1997). We used antibodies that recognize species referred to as
Ab1-42 and Ab1-X. The Ab1-42 ELISA detects only Ab1-42, and the Ab1-x
ELISA detects Ab1-40, Ab1-42, and Ab1-43, as well as C-terminally truncated
forms of Ab containing amino acids 1–28.
Morris Water Maze
Experimenters were blind to the genotypes of the mice for all behavioral analy-
ses (Morris water maze, elevated plus maze, and open field). Only male mice
were used for behavioral assessment due to high levels of variability observed
in female mice (data not shown). The water maze consisted of a pool (122 cm in
diameter) containing opaque water (20C ± 1C) and a platform (14 cm in
diameter) submerged 1.5 cm under the water. Mice were first given four pre-
trainings (90 s/trial, day 0) in which they had to swim down a channel (15 3
122 cm) and mount a platformhidden 1.5 cm below the water surfaceat the mid-
dle of thechannel.Hidden-platformtraining (days1–5) consisted of tensessions
(two per day, 2 hr apart), each with three trials. The platform location remained
constant in the hidden-platform sessions, and the entry points were changed
semirandomly between trials. The maximum trial time was 60 s. Mice that failed
to find the platform were led to it and placed on it for 15 s. A day after the last
hidden-platform training session, a probe trial was conducted by removing
the platform and allowing mice to search in the pool for 60 s. For cued training
sessions (days 9–11), the platform was marked with a visible beacon, and the
mice were trained to locate the platform over five sessions (two per day for
the first 2 days, 4 hr apart; one for the last day), each with two trials. The platform
location was changed for each session. Time to reach the platform, time in tar-
get quadrant, platform crossings, path length, and swim speed were recorded
with an EthoVision video tracking system (Noldus, Netherlands).
Elevated Plus Maze
The elevated plus maze consisted of two open arms (without walls) and two
enclosed arms (with walls) elevated 63 cm above the ground (Hamilton-Kinder,
Poway, CA). Mice were first allowed to habituate in the testing room under dim
light for 30 min before testing. During testing, mice were placed at the junction
between the open and closed arms of the plus maze and allowed to explore for
10 min. As a measure of disinhibition, we measured the ratios of the distance
traveled and time spent in the open arms to the total distance traveled and time
spent in both open and closed arms. The maze was thoroughly cleaned with
70% ethanol between testing sessions.
Open Field Test
An automated Flex-Field/Open Field Photobeam Activity System (San Diego
Instruments, San Diego, CA) was used to assess spontaneous motor activity
and within-session habituation to a novel environment. Mice were placed in
one of four identical clear plastic chambers (41 3 41 3 30 cm) for 15 min,Neuron 60, 247–257, October 23, 2008 ª2008 Elsevier Inc. 255
Neuron
Cystatin C Inhibits Ab Degradation by Cathepsin Bwith two 16 3 16 photobeam arrays to detect horizontal and vertical move-
ments. Total movements (ambulations) in the outer periphery and center of
the open field were reported. The apparatus was thoroughly cleaned with
70% ethanol between trials.
Electrophysiology
The experimenter was blind to the genotypes of the mice for all electrophysio-
logical analyses. Acute hippocampal slices (350 mm, coronal) were prepared
from 3- to 4-month-old mice. Briefly, brains were quickly removed and sliced
with a Vibratome 3000 (Vibratome, St. Louis, MO) in ice-cold solution oxygen-
ated with 95% O2/5% CO2 containing (in mM) 2.5 KCl, 1.25 NaPO4, 10 MgSO4,
0.5 CaCl2, 26 NaHCO3, 11 glucose, and 234 sucrose (300–305 mOsm). Slices
were maintained in continuously oxygenated solution containing (in mM)
2.5 KCl, 126 NaCl, 10 glucose, 1.25 NaH2PO4, 1 MgSO4, 2 CaCl2, and
26 NaHCO3 (pH z7.4 when gassed with a mixture of 95% O2/5% CO2) at
30C for 30 min, and allowed to recover at room temperature for at least
45 min before being transferred to a submerged recording chamber. Field
EPSPs were recorded with glass electrodes (3 MU tip resistance) filled with
1 M NaCl and 25 mM HEPES (pH = 7.3) and evoked every 20 s with a bipolar
tungsten electrode (FHC, Bowdoin, ME). Recordings were filtered at 2 kHz
(3 dB, eight-pole Bessel), digitally sampled at 20 kHz with a Multiclamp
700A amplifier (Molecular Devices, Foster City, CA), and acquired with a Digi-
data-1322A digitizer and pClamp 9.2 software. Data were analyzed offline
with pClamp9 software and Origin 8.0 (OriginLab, Northampton, MA).
The stimulating electrode was placed in the stratum radiatum (for CA1 I/O),
LPP (for paired pulse), or MPP (for DG I/O and LTP). For recordings in the DG,
the bathing solution contained 10 mM GABAzine (Tocris) to block inhibitory
transmission. After a 15 min stable baseline was established, LTP was induced
by theta burst stimulation (a set of ten bursts repeated ten times every 15 s;
each burst, consisting of four pulses at 100 Hz, was repeated at 5 Hz).
Statistical Analysis
Statistical analyses were conducted with Graphpad Prism (San Diego, CA) or
SPSS (Chicago, IL). Survival data were analyzed with Kaplan-Meier statistics
and post hoc log rank tests. Differences among multiple means with one
variable (CysC genotype) were evaluated by one-way ANOVA and the
Tukey-Kramer post hoc test. Differences among multiple means with two
variables (CysC and hAPP genotypes or CysC and CatB genotypes) were
evaluated by two-way ANOVA and Bonferroni multiple comparison post hoc
test. Differences between two means were assessed with unpaired, two-tailed
t test or Mann-Whitney U test. Age-adjusted plaque load was assessed with
multivariate loglinear regression analyses performed in SPSS. The loga-
rithm-transformed plaque load was regressed against both age and genotype
(as a dummy variable). Only values with p < 0.05 were accepted as significant.
SUPPLEMENTAL DATA
The Supplemental Data include two tables and four figures and can be
found with this article online at http://www.neuron.org/supplemental/
S0896-6273(08)00838-6.
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